Ironwood Pharmaceuticals Inc. Class A Common Stock (IRWD)
Stock · NASDAQ · Health Care
$3.49as of 10/16/2026
Price chart
Active signals
IRWD Signal Track Record
How signals performed across all stocks →What IRWD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -0.2% | 46% | September 17, 2026 |
| Bollinger Band Breakout | 23 | -0.2% | 48% | September 22, 2026 |
| Bollinger Band Breakdown | 20 | -1.8% | 45% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -2.5% | 24% | September 30, 2026 |
| Any 20-session window (baseline) | -0.4% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IRWD
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric pati…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 100
- Website
- www.ironwoodpharma.com/
Fundamentals
- 1-day range
- $3.63$3.87
- Market cap
- $701.25M
- P/E (trailing)
- 4.68
- P/E (forward)
- 2.51
- EPS (trailing)
- $0.76
- Dividend yield
- —
- Beta
- 0.22
- Avg. volume
- 1.98M
How Ironwood Pharmaceuticals Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Ironwood Pharmaceuticals Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ironwood Pharmaceuticals Appoints Tammi Gaskins CEO, Effective Jan. 1, 2027benzinga · 10/16/2026
- Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?Yahoo · 10/7/2026
- Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - BuySeekingAlpha · 10/7/2026
- Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 10/5/2026
- PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Yahoo · 9/30/2026
- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryYahoo · 9/14/2026
- Ironwood: Medicare Is Not The Problem I Thought It WasSeekingAlpha · 9/11/2026
Insider Activity
Insider Actions →- Alexander J. Denner · September 15, 2026 · Grant3.7K
- Silber Jeffrey · July 20, 2026 · Grant137.0K
- Silver Ronald · July 7, 2026 · Sale127.9K @ $4.52
- Jay Shepard · June 16, 2026 · Grant63.5K
- Kessler Marla L · June 16, 2026 · Grant63.5K
- Currie Mark G · June 16, 2026 · Grant63.5K
- Duane Jon R · June 16, 2026 · Grant63.5K
- Julie McHugh · June 16, 2026 · Sale21.6K @ $3.73
- Julie McHugh · June 16, 2026 · Grant63.5K
- Catherine Moukheibir · June 16, 2026 · Grant63.5K
- Alexander J. Denner · June 16, 2026 · Grant63.5K
- Alexander J. Denner · June 15, 2026 · Grant4.1K
- Silver Ronald · May 19, 2026 · Grant25.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 163.15M
- Total value held
- $545.10M
- Institutional holders
- 218
- Unknown15.03M
- Unknown13.36M
- Unknown12.13M
- Unknown9.19M
- Unknown8.68M
- Unknown8.06M
- Unknown7.54M
- Unknown7.46M
- Unknown6.58M
- Unknown6.10M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Ironwood Pharmaceuticals names Tammi Gaskins as CEO
Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.
Ironwood Pharmaceuticals names Tammi Gaskins as CEO. Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.